Jeffrey G Marblestone

Summary

Publications

  1. ncbi request reprint Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference
    Jeffrey G Marblestone
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    IDrugs 12:750-3. 2009
  2. pmc Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins
    Jeffrey G Marblestone
    Progenra Inc, Malvern, PA 19355, USA
    Biochim Biophys Acta 1823:2094-7. 2012
  3. doi request reprint Novel approach for characterizing ubiquitin E3 ligase function
    Jeffrey G Marblestone
    Progenra, Inc, Malvern, Pennsylvania, USA
    J Biomol Screen 15:1220-8. 2010
  4. doi request reprint Targeting the ubiquitin E3 ligase MuRF1 to inhibit muscle atrophy
    Michael J Eddins
    Progenra, Inc, 277 Great Valley Parkway, Malvern, PA 19355, USA
    Cell Biochem Biophys 60:113-8. 2011
  5. doi request reprint Comprehensive ubiquitin E2 profiling of ten ubiquitin E3 ligases
    Jeffrey G Marblestone
    Progenra, Inc, 277 Great Valley Parkway, Malvern, PA 19355, USA
    Cell Biochem Biophys 67:161-7. 2013
  6. pmc Deubiquitinating enzymes as novel anticancer targets
    Benjamin Nicholson
    Progenra, Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Future Oncol 3:191-9. 2007
  7. pmc Strategies for the identification of ubiquitin ligase inhibitors
    Seth J Goldenberg
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Biochem Soc Trans 38:132-6. 2010

Detail Information

Publications7

  1. ncbi request reprint Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference
    Jeffrey G Marblestone
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    IDrugs 12:750-3. 2009
    ..Investigational drugs discussed include MLN-4924 and MLN-9708 (both Millennium Pharmaceuticals Inc), P-005091 (Progenra Inc), CEP-18770 (Cephalon Inc) and carfilzomib (Proteolix Inc)...
  2. pmc Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins
    Jeffrey G Marblestone
    Progenra Inc, Malvern, PA 19355, USA
    Biochim Biophys Acta 1823:2094-7. 2012
    ..This article is part of a Special Issue entitled: Ubiquitin Drug Discovery and Diagnostics...
  3. doi request reprint Novel approach for characterizing ubiquitin E3 ligase function
    Jeffrey G Marblestone
    Progenra, Inc, Malvern, Pennsylvania, USA
    J Biomol Screen 15:1220-8. 2010
    ..As the number of E3 ligases associated with various disease states increases, the ability to quantitate the activity of these enzymes in an expeditious manner becomes imperative in drug discovery...
  4. doi request reprint Targeting the ubiquitin E3 ligase MuRF1 to inhibit muscle atrophy
    Michael J Eddins
    Progenra, Inc, 277 Great Valley Parkway, Malvern, PA 19355, USA
    Cell Biochem Biophys 60:113-8. 2011
    ..Thus MuRF1 can be targeted in a specific manner and produce positive results in cellular atrophy models...
  5. doi request reprint Comprehensive ubiquitin E2 profiling of ten ubiquitin E3 ligases
    Jeffrey G Marblestone
    Progenra, Inc, 277 Great Valley Parkway, Malvern, PA 19355, USA
    Cell Biochem Biophys 67:161-7. 2013
    ..Finally, substrate ubiquitylation was assayed for the E3 ligase MuRF1 using various E2/MuRF1 pairs. These studies demonstrate the utility of identifying the correct E2/E3 pair to monitor specific substrate ubiquitylation. ..
  6. pmc Deubiquitinating enzymes as novel anticancer targets
    Benjamin Nicholson
    Progenra, Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Future Oncol 3:191-9. 2007
    ..In the following review, this fascinating class of regulatory enzymes will be described, and specific examples of DUBs that are viable targets for anticancer therapy will be considered...
  7. pmc Strategies for the identification of ubiquitin ligase inhibitors
    Seth J Goldenberg
    Progenra Inc, 271A Great Valley Parkway, Malvern, PA 19355, USA
    Biochem Soc Trans 38:132-6. 2010
    ..In this paper, we will discuss current platforms that report on E3 ligase activity and can detect E3 inhibitors, and underline the advantages and disadvantages of each approach...